Go Pro
TSE:SVA

Sernova Q2 2026 Earnings Report

Sernova logo
C$0.10 -0.01 (-5.00%)
As of 09/23/2026 04:24 PM Eastern

Sernova EPS Results

Actual EPS
C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sernova Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sernova Announcement Details

Quarter
Q2 2026
Time
N/A
Conference Call Date
Thursday, June 11, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Sernova Earnings Headlines

FY2026 Earnings Forecast for Sernova Issued By HC Wainwright
Elon gets it. Do you?
Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news. Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point.tc pixel
See More Sernova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova and other key companies, straight to your email.

About Sernova

Sernova (TSE:SVA) Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.

View Sernova Profile